Literature DB >> 11090091

Polyclonal hematopoiesis with variable telomere shortening in human long-term allogeneic marrow graft recipients.

G Mathioudakis1, R Storb, P A McSweeney, B Torok-Storb, P M Lansdorp, T H Brümmendorf, M J Gass, E M Bryant, J Storek, M E Flowers, T Gooley, R A Nash.   

Abstract

Donor-derived hematopoiesis was assessed in 17 patients who received allogeneic marrow grafts from HLA-matched siblings between 1971 and 1980. Complete blood counts were normal or near normal in all patients except one. Chimerism analyses, using either dual-color XY-chromosome fluorescence in situ hybridization (FISH) or analysis of variable number tandem repeat loci, indicated that 15 out of 16 patients had greater than 97% donor-derived hematopoiesis, whereas 1 patient had indeterminate chimerism. All 12 recipients of grafts from female donors exhibited polyclonal hematopoiesis by X-linked clonal analysis with the use of molecular probes. Of the 17 recipients, 9 exhibited a less than 1.0-kilobase shortening of granulocyte telomere length compared with their respective donors, according to terminal restriction fragment analysis or flow-FISH with a fluorescein-labeled peptide nucleic acid probe. These data suggest that under standard transplantation conditions, the stem cell proliferative potential is not compromised during hematopoietic reconstitution. (Blood. 2000;96:3991-3994)

Entities:  

Mesh:

Year:  2000        PMID: 11090091

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  9 in total

Review 1.  PNA Technology.

Authors:  Peter E Nielsen
Journal:  Mol Biotechnol       Date:  2004-03       Impact factor: 2.695

2.  Isolation and therapeutic potential of human haemopoietic stem cells.

Authors:  Andrew D Clark; Heather G Jørgensen; Joanne Mountford; Tessa L Holyoake
Journal:  Cytotechnology       Date:  2003-03       Impact factor: 2.058

3.  Age-adjusted recipient pretransplantation telomere length and treatment-related mortality after hematopoietic stem cell transplantation.

Authors:  Régis Peffault de Latour; Rodrigo T Calado; Marc Busson; Jeffrey Abrams; Nadir Adoui; Marie Robin; Jérôme Larghero; Nathalie Dhedin; Alienor Xhaard; Emmanuel Clave; Dominique Charron; Antoine Toubert; Pascale Loiseau; Gérard Socié; Neal S Young
Journal:  Blood       Date:  2012-09-04       Impact factor: 22.113

4.  Impact of donor age on outcome after allogeneic hematopoietic cell transplantation.

Authors:  Andrew R Rezvani; Barry E Storer; Katherine A Guthrie; H Gary Schoch; David G Maloney; Brenda M Sandmaier; Rainer Storb
Journal:  Biol Blood Marrow Transplant       Date:  2014-09-30       Impact factor: 5.742

Review 5.  The role of telomere biology in bone marrow failure and other disorders.

Authors:  Sharon A Savage; Blanche P Alter
Journal:  Mech Ageing Dev       Date:  2007-11-19       Impact factor: 5.432

Review 6.  Severe aplastic anemia: allogeneic bone marrow transplantation as first-line treatment.

Authors:  George E Georges; Kris Doney; Rainer Storb
Journal:  Blood Adv       Date:  2018-08-14

7.  Epigenetic Aging and Hematopoietic Cell Transplantation in Patients With Severe Aplastic Anemia.

Authors:  Rotana Alsaggaf; Shilpa Katta; Tao Wang; Belynda D Hicks; Bin Zhu; Stephen R Spellman; Stephanie J Lee; Steve Horvath; Shahinaz M Gadalla
Journal:  Transplant Cell Ther       Date:  2021-01-16

8.  Prediction of graft-versus-host disease in humans by donor gene-expression profiling.

Authors:  Chantal Baron; Roland Somogyi; Larry D Greller; Vincent Rineau; Peter Wilkinson; Carolyn R Cho; Mark J Cameron; David J Kelvin; Pierre Chagnon; Denis-Claude Roy; Lambert Busque; Rafick-Pierre Sékaly; Claude Perreault
Journal:  PLoS Med       Date:  2007-01       Impact factor: 11.069

9.  Comparable Effects of the Androgen Derivatives Danazol, Oxymetholone and Nandrolone on Telomerase Activity in Human Primary Hematopoietic Cells from Patients with Dyskeratosis Congenita.

Authors:  Margherita Vieri; Martin Kirschner; Mareike Tometten; Anne Abels; Benjamin Rolles; Susanne Isfort; Jens Panse; Tim H Brümmendorf; Fabian Beier
Journal:  Int J Mol Sci       Date:  2020-09-29       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.